Responsible for the uptake and growth of Tutivia for post-kidney transplant risk assessment for acute rejection across the Southeast United States.

• Accountable for driving AlloSure sales and fostering growth across Georgia, Alabama, and Mississippi, spanning both transplant center and community nephrology environments.• Delivered consistent and impressive growth rates at renowned transplant centers including UMMC, UAB, Emory, Piedmont, and Children's of Atlanta: Q1 (72%), Q2 (54%), Q3 (54%), Q4 (44%).• Pioneered the development of a transitional testing protocol in collaboration with Emory. This innovative approach allowed stable post-transplant patients to transition from a monthly to a bi-monthly belatacept infusion schedule, resulting in increased AlloSure frequency to bi-weekly draws.• Forged a strategic partnership with UAB to advance dd-cfDNA testing within their xenotransplantation program.• Demonstrated exceptional sales performance throughout 2022, consistently exceeding quotas: Q1 (120%), Q2 (100%), Q3 (116%), Q4 (96%), culminating in a final attainment of 108%.

• Spearheaded the successful launch of the potassium binder Veltassa across 15 prominent medical centers in Northern Alabama.• Pioneered the establishment of a previously untapped nephrology market for the treatment of chronic hyperkalemia, leveraging the HUB patient-access model.• Secured formulary approval at influential healthcare institutions, including UAB Medical Center, the Huntsville Hospital System (comprising five institutions), and various CHS hospitals throughout the territory.• Introduced a new indication for Invokana (Diabetic Kidney Disease) within the nephrology sector in 2020, achieving outstanding growth over the national baseline and ranking in the top one-third of the nation.• Notable contributions to the organization include participation in the Customer Targeting Task Force in 2019, active involvement in the Sales Operations Committee in 2018, and a key role on the Field Advisory Committee in 2016.

• Successfully introduced new antibiotics, namely Teflaro, Dalvance, and Avycaz, to 11 medical centers spanning North Alabama, Northeast Mississippi, and Tennessee, achieving unrestricted formulary access within the first year of their launch.• Introduced the COPD product line featuring Daliresp and Tudorza across 10 medical centers in North Alabama and Northeast Mississippi.• Held responsibility for various medical specialties, including Infectious Disease, Pulmonology, Pharmacy, Hospitalists, Surgery, Microbiology, Emergency Medicine, and Infusion Centers.• Recognitions and Achievements:• 2013: Earned the prestigious title of International Sales Champion with a #1 national ranking.• 2014: Received the honor of being inducted into the President's Club.

• Oversaw sales revenue of approximately $68 million within the North Alabama district, encompassing Huntsville, Florence, and Birmingham.• Provided instruction, training, and coaching to a team of sales professionals, focusing on product knowledge, sales techniques, and business analysis.• Implemented job performance evaluations and individual development plans for each sales professional, resulting in increased sales force efficiency and productivity.• Organized and executed various sales and sales management meetings.• Held responsibilities for daily planning, promotion budgeting, business analytics, and administration of approval processes.• Additional Achievements:• Served on the Sales Operations Champions Committee (2009-10).• Member of the Southeast Area Incentive Compensation Committee (2010).• Accomplishments in 2010:• Ranked 2nd out of 7 in the Birmingham Region.• Ranked 5th out of 42 in the Southeast Area.• Ranked 22nd out of 242 nationwide in sales rankings.

• Honored with the "Center of Influence" representative role, entrusted with overseeing the largest accounts within the Northern Alabama territory.• Played a pivotal role in promoting the exclusive use of Lovenox as the preferred LMWH (Low Molecular Weight Heparin) on the Chest Pain Center protocol at Huntsville Hospital during TI.• Collaborated with Quality Improvement and Risk Management teams at Decatur General, Eliza Coffee Memorial, Crestwood Medical Center, Helen Keller, and Shoals hospitals to devise customized in-hospital DVT prophylaxis protocols.• Provided consultation to Emergency Department, Quality Improvement, and Cardiology staff at Decatur General Hospital to formulate Chest Pain Center protocols aligned with national ACS (American College of Cardiology) treatment guidelines.• Additional Achievements:• Held the role of Area Sales Trainer for Birmingham North District from 2005 to 2006.• Recognitions and Awards:• 2008: Appointed as Interim District Sales Manager in Knoxville, TN.• 2007: Named Representative of the Quarter in Q1.• 2006: Received the Regional Sales Champion Awards Trip.• 2005: Achieved the Regional Sales Champion Award.• 2005: Earned the title of Representative of the Quarter in Q1, Q3, and Q4.• 2005: Recognized as the Representative of the Year in the North Birmingham District.

• Provided instruction, training, and coaching to a team of sales professionals, focusing on product knowledge, sales techniques, and business analysis.• Implemented job performance evaluations and individual development plans for each sales professional, resulting in increased sales force efficiency and productivity.• Organized and executed various sales and sales management meetings.• Held responsibilities for daily planning, promotion budgeting, business analytics, and administration of approval processes.

• Maintained a consistent position within the top 25% of all sales associates both at the regional and national levels.• Received the prestigious regional "Top Gun" sales award in both 2000 and 2001.• Undertook the challenging task of inheriting a territory ranked at the bottom of the national list (528/528) in 1998, orchestrating a remarkable ascent of 402 positions to reach #126 within a span of just 12 months.• Additional Achievements:• Acted as the Area Sales Trainer for the Louisville District in both 2000 and 2001.